ocugen_4C_LOGO (002).png
Ocugen to Present at Pharma Market Research Conference
January 31, 2024 08:00 ET | Ocugen
MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023 06:30 ET | Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023 07:30 ET | Ocugen
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023 16:32 ET | Ocugen
Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease ...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
June 09, 2023 16:05 ET | Ocugen
MALVERN, Pa., June 09, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
April 28, 2023 07:00 ET | Ocugen
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
April 11, 2023 18:20 ET | Ocugen
MALVERN, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
March 27, 2023 08:00 ET | Ocugen
U.S. Food & Drug Administration (FDA) approves enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with...
ocugen_4C_LOGO (002).png
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023 06:00 ET | Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...
ocugen_4C_LOGO (002).png
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
December 16, 2022 06:30 ET | Ocugen
MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...